IL-21 antagonists

Details IL-21 antagonists IL-21 antagonists

2005-08-16

2005-08-16

Andres, Janet (Department: 1647)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069100, C435S071100, C435S320100, C435S471000, C435S325000, C435S255100, C536S023500, C530S351000

Reexamination Certificate

active

06929932

ABSTRACT:
The polypeptides, and the polynucleotides encoding for them, described herein are IL-21 antagonists that bind with specificity and exhibit an EC50that is not detectable in receptor binding studies. These molecules have mutations in the D helix of the IL-21 molecule, and can be used to inhibit the activity of IL-21 with its cognate receptor.

REFERENCES:
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 00/53761 (2000-09-01), None
patent: 03/087320 (2003-10-01), None
1483966. Marra, WashU-HHMI Mouse EST Project, 1996.
Brandt et al., “Generation of Antagonists by Amino Acid Replacement in the D-Helix of Human IL-21,” : abs. 119, 2001.
Parrish-Novak et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature408:57-63, 2000.
Parrish-Novak et al., “Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses,”J. of Leukocyte Biol., 72:856-863, 2002.

Affiliated with

Also associated with

Rating

IL-21 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-21 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-21 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3450146